iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Glenmark Pharmaceuticals gains on launching type-2 diabetes drug in India

6 Oct 2022 , 09:50 AM

The said drug is marketed under the brand name LOBG; it contains Lobeglitazone (0.5 mg) and to be taken once daily under prescription to improve glycemic control in adult diabetic patients, the company stated. Indians have a high prevalence of insulin resistance and that makes LOBG an appealing treatment option in managing uncontrolled type 2 diabetes among insulin&8208;resistant diabetic patients. With this launch, the company aims to improve glycemic levels in uncontrolled diabetics and create a new pathway to treat insulin resistance in India, the drug maker said in the press release. The pharmaceutical company said that it had earlier received approval from the Indian drug regulator, Drug Controller General of India, for manufacturing and marketing Lobeglitazone based on a randomized, double&8208;blind Phase 3 clinical trial conducted on adult type 2 diabetic patients, aged 18 years and older. The results of this trial have shown a faster and improved glycemic control with Lobeglitazone, it added. On the occasion of the launch, Alok Malik, EVP & Business Head &8208; India Formulations, Glenmark Pharmaceuticals, said, ?As per the International Diabetes Federation, diabetes affects 74 million adults in India, of which, around 40% of them seem to be insulin&8208;resistant. As a leading solutions provider in India for the treatment of diabetes, we are proud to introduce LOBG; an innovative and affordable drug, which will help in tackling insulin resistance among adult patients suffering from uncontrolled type 2 diabetes in the country.? In 2015, Glenmark launched the DPP4 inhibitor – Teneligliptin, followed by a fixed dose combination (FDC) of Teneligliptin + Metformin. In continuation towards its legacy, Glenmark launched Remogliflozin, a novel SGLT&8208;2 inhibitor in 2019 after its first global approval in India and subsequently launched its combinations with metformin and Vildagliptin. According to IQVIA sales data for the 12 month period ending August 2022, the market for oral anti&8208;diabetic drugs in India is estimated to be Rs 11,725 crore with an annual growth of 7% against the corresponding period last year (MAT Aug 2021). Glenmark Pharmaceuticals is a global pharmaceutical company with a presence across specialty, generics, and OTC businesses. The companys consolidated net profit declined 37.20% to Rs 192.53 crore on a 7.67% fall in sales to Rs 2,720.10 crore in Q1 FY23 over Q1 FY22. Powered by Capital Market – Live News

Related Tags

  • capital market
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.